

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup>:</b> C12N 5/10, 15/11, 15/12, 15/30, 15/31, 15/33, 15/63	<b>A1</b>	<b>(11) International Publication Number:</b> WO 94/24267 <b>(43) International Publication Date:</b> 27 October 1994 (27.10.94)
<b>(21) International Application Number:</b> PCT/US94/04367 <b>(22) International Filing Date:</b> 20 April 1994 (20.04.94) <b>(30) Priority Data:</b> 08/049,259 20 April 1993 (20.04.93) US <b>(60) Parent Application or Grant</b> <b>(63) Related by Continuation</b> US 08/049,259 (CIP) Filed on 20 April 1993 (20.04.93) <b>(71) Applicant (for all designated States except US):</b> ROBINSON, William, S. [US/US]; 1630 Escobita Avenue, Palo Alto, CA 94306 (US). <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> CHU, Keting [CN/US]; 1630 Escobita Avenue, Palo Alto, CA 94306 (US). <b>(74) Agents:</b> LEHNHARDT, Susan, K. et al.; Morrison & Foerster, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).	<b>(81) Designated States:</b> AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>	
<b>(54) Title:</b> METHODS AND MATERIALS FOR TREATMENT OF INDIVIDUALS INFECTED WITH INTRACELLULAR INFEC- TIOUS AGENTS  <b>(57) Abstract</b>  Recombinant polynucleotides are provided that confer at least partial immunity on an individual to an infectious intracellular pathogenic agent. The recombinant polynucleotides encode a costimulatory factor and/or a target antigen polypeptide. The immune response that confers the immunity results from the expression of both polypeptides in an antigen presenting cell in the individual. The immunity is to the pathogenic agent that naturally encodes the target antigen polypeptide.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LI	Lithuania	SN	Senegal
CN	China	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
CZ	Czech Republic	LV	Latvia	TJ	Tajikistan
DE	Germany	MC	Monaco	TT	Trinidad and Tobago
DK	Denmark	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali	UZ	Uzbekistan
FR	France	MN	Mongolia	VN	Viet Nam
GA	Gabon				

-1-

5        METHODS AND MATERIALS FOR TREATMENT OF INDIVIDUALS  
         INFECTED WITH INTRACELLULAR INFECTIOUS AGENTS

Field of the Invention

10                This invention relates to methods of preventing  
                 new infections, curing current infections and treating  
                 chronic infections caused by intracellular infectious  
                 agents. The methods encompass using gene therapy to  
                 enhance the interaction between ligands that costimulate  
15        T cell activation. More specifically, this invention  
                 relates to materials and methods of gene therapy in which  
                 genes encoding an antigen from an infectious agent and  
                 ligands that costimulate T cell activation are co-  
                 expressed in the cells of the host animal to prevent or  
20        treat chronic infection. This method stimulates or  
                 enhances immune responses to antigens of infectious  
                 agents by enhancing the antigen-specific T cell response  
                 thus providing protection against new infection or  
                 terminating chronic infection.

25

Background of the Invention

                 Many infectious agents are capable of causing  
                 infection and disease in a host organism; examples of  
                 such infectious agents include protozoa, fungi, bacteria,  
30        viruses and even worms. Of these infectious agents,  
                 those with the mechanism to act intracellularly pose the  
                 most significant challenge for prevention and treatment.  
                 This is particularly true where the host of the  
                 intracellular infectious agent is a mammal, such as man.

35

-2-

Mammals have a complex immune system which has several different mechanisms for defending against an invasion by an infectious agent. Under normal circumstances, the immune system functions to ultimately  
5 eliminate the infectious agent from the mammalian host's system. Most infections are self-limiting because the mammalian immune system is generally able to eliminate the infectious agents. Problems arise, however, when the  
10 immune system is unable to, or does not, respond to the presence of an infectious agent. In this scenario, infections can become chronic and can persist for many years or even the life-time of the infected human or animal; often resulting in serious disease.

Traditional, standard vaccines expose the  
15 immune system to a foreign antigen such as those of infectious agents to elicit an antigen-specific immune response. The immune response is most often humoral and not cellular, that is, it results in production of antibodies but not T cell-based immunity as discussed  
20 below. Effective vaccination prevents infection or modifies diseases resulting from infection caused by the infectious agent to which the vaccine is directed.

Immune responses that elicit neutralizing antibodies are sufficient for preventing infections with  
25 certain viruses. Murphy et al. (1990). Thus, infection by these viruses can be prevented by vaccination with antigens that elicit neutralizing antibodies. For some viruses and non-virus infectious agents, however, neutralizing antibodies either cannot be elicited or, if  
30 elicited, are insufficient to prevent infection and/or disease progression.

Two traditional vaccine types are killed viruses and live attenuated viruses. Killed viruses consist of either whole virions or other infectious  
35 agents the infectivity of which has been inactivated.

-3-

These vaccines may also consist of antigenic subunits or component parts of virions or other infectious agents. These vaccines are administered by parenteral inoculation or exposure to mucous membranes. Live attenuated  
5 vaccines consist of live virus or other infectious agents with genetically altered virulence. When used for vaccination, these vaccines cause a reduced form of the disease, or no disease at all.

A third vaccine approach has been investigated  
10 and used experimentally but is not yet in clinical use. This approach is the utilization of live agents such as viruses or bacteria as vectors to express vaccine antigens of heterologous infectious agents. A gene or nucleotide sequence encoding the antigen is expressed by  
15 the vector and when used in vaccination, exposes the host to the antigen. An immune response to the antigen is expected to protect the host from the infectious agent from which the antigen was derived.

Examples of killed vaccines include tetanus  
20 toxoid, influenza virus subunit, rabies, polio and HBV. Examples of live attenuated vaccines include Salmonella typhi Ty 21-a and live vaccines for polio, measles, rubella, mumps, smallpox and yellow fever viruses. Examples of live vectors used to express heterologous  
25 vaccine antigens include vaccinia virus, adenovirus, adeno-associated virus and S. typhi Ty 21-a strain.

Examples of chronic infections associated with significant morbidity and early death include the two human hepatitis viruses, hepatitis B virus (HBV) and  
30 hepatitis C virus (HCV) which cause chronic hepatitis, cirrhosis and liver cancer. HBV infection in man closely parallels the infections caused by the closely related hepadnaviruses in certain animals including ground squirrel hepatitis virus (GSHV) which infects the Beechey  
35 ground squirrels, woodchuck hepatitis virus (WHV) which

-4-

infects woodchucks, and duck hepatitis B virus (DHBV) which infects ducks. Robinson, in, Virology, 2nd Ed., ed. B. Fields, Raven Press, New York, pp. 2137-2169 (1990).

5 Additional examples of chronic infections in man caused by viral infectious agents include those caused by the human retroviruses: human immunodeficiency viruses (HIV-1 and HIV-2), which cause acquired immune deficiency syndrome (AIDS); and human T lymphotropic  
10 viruses (HTLV-1 and HTLV-2) which cause T cell leukemia and myelopathies. Many other infections such as human herpes viruses including the herpes simplex virus (HSV) types 1 and 2, Epstein Barr virus (EBV), cytomegalovirus (CMV), varicella-zoster virus (VZV) and human herpes  
15 virus 6 (HHV-6) are not eradicated by host mechanisms, but rather become chronic and in this state may cause disease. Chronic infection with human papilloma viruses is associated with cervical carcinoma. Numerous other viruses and other infectious agents replicate  
20 intracellularly and may become chronic when host defense mechanisms fail to eliminate them. These include pathogenic protozoa (e.g., Pneumocystis carinii, Trypanosoma, Leishmania, Malaria and Toxoplasma gondii), bacteria (e.g., mycobacteria, salmonella and listeria),  
25 and fungi (e.g., candida and aspergillus).

Treatment of chronic virus infections resulting in significant clinical benefit has not been successful largely because such treatments fail to terminate the infection or eliminate the virus. Previous treatments  
30 include administration of small chemical compounds such as nucleoside analogs or biologically active proteins such as interferons. These treatments inhibit virus replication but do not eliminate virus from cells or virus infected cells themselves and may result in limited  
35 disease improvement only during their administration.

-5-

Unfortunately, viral infections are often exacerbated when administration of the drug is discontinued.

Common antiviral treatments include nucleoside analogues such as azidothymidine (AZT), dideoxyinosine (DDI) and dideoxycytidine (DDC) for chronic HIV infection and associated AIDS, and adenine arabinoside (araA) for HBV infection and associated liver disease. Interferons similarly suppress HBV and HCV during therapy of chronic infection but the virus usually returns to pretreatment levels and the disease is exacerbated when therapy is discontinued.

One important mechanism employed by the mammalian immune system for controlling and ultimately eliminating ongoing infections by intracellular infectious agents is the activated cellular immune response by activation of certain T cells. T cell activation results in a cytotoxic T lymphocyte (CTL) response directed at viral (or other intracellular infectious agents) antigens on the infected cell surface and elimination of the infected cells. Guilhot et al., J. Virol., 66:2670-2678 (1992). This ultimately results in the elimination of infected cells and the infectious agent within the infected cells. For a general discussion of immune responses to viral infectious agents, see Whitton et al., in, Virology, 2nd Ed., ed. B. Fields, Raven Press, New York, pp. 369-381 (1990); and Roitt, Essential Immunology, 7th Ed. (1991).

Activation of T cells occurs when the T cell receptor (TCR) forms a ternary complex with an antigen peptide complexed with a self-MHC (major histocompatibility complex) molecule on the surface of professional antigen-presenting cells (APC). Professional APCs include macrophages and activated B cells. Townsend et al., Cell, 44:959-968 (1986); Townsend et al., Ann. Rev. Immunol., 7:601-624 (1989);

-6-

Bjorkman et al., Nature, 329:512-518 (1987); and  
Jardetsky et al., Nature, 353:326-329 (1991). The  
ternary complex allows for a costimulatory signal to pass  
between the cells. Activation of T cells requires not  
5 only recognition of the antigen peptide-MHC complex by  
the TCR, but also the interaction of "costimulatory  
factors," located on the surface of APCs, with specific  
molecules on the surface of the T cells, the  
"costimulatory ligand." Freeman et al., J. Exp. Med.,  
10 174:625-691 (1991). As used herein, costimulatory  
factors on APCs include, but are not limited to, the B7-1  
protein which specifically binds CD28 and CTL-4 proteins  
on the surface of T cells and the B7-2 and B7-3 proteins  
which bind CTLA-4 in T cell activation. Boussiotis et  
15 al., Proc. Natl. Acad. Sci. USA, 90:11059-11063 (1993).  
B7 ligands are expressed exclusively by professional  
APCs. Freeman et al., J. Exp. Med., 174:625-631 (1991);  
Razi-Wolf et al. (1992); and Larsen et al. (1992). The  
interaction of CD28 and B7-1 has been shown to be  
20 essential for T cell activation. Jenkins et al., J.  
Immunol., 140:3324-3330 (1988); Linsley et al. (1990);  
Linsley et al., J. Exp. Med., 173:721-730 (1991); Gimmi  
et al., Proc. Natl. Acad. Sci. USA, 88:6575-6579 (1991);  
Jenkins et al., J. Immunol., 147:2461-2466 (1991); and  
25 Harding et al. (1992).

One of the costimulatory molecules found on the  
APC is the B7 protein which is the ligand for the T cell  
surface differentiation antigen CD28. B7 expression,  
typically effected by professional APCs, has been found  
30 to be of critical importance to the activation of naive  
T cells. Larsen et al., J. Exp. Med., 176:1215-1220  
(1992). Other studies have shown that there is a direct  
relationship between the increase in functional activity  
of the T cell with the increase in B7 expression.  
35 Razi-Wolf et al., Proc. Natl. Acad. Sci. USA, 89:4210-



-7-

4214 (1992). T cells are rendered anergic when they encounter antigen peptides on cells lacking the costimulatory ligand for which CD28 is a receptor. Harding et al., Nature, 356:607-609 (1992).

5           Viral antigens can be degraded in infected cells when specific viral antigen peptide fragments that bind MHC class I molecules are presented at the cell surface where they serve as targets for MHC restricted CTL. Whitton et al. (1990). However, most infected  
10 cells in virally infected hosts are not professional APCs expressing costimulatory proteins. Furthermore, infected cells lacking costimulatory molecules such as B7-1, B7-2, B7-3 may not elicit an effective cellular immune  
15 response. When such mechanisms are inadequate and fail to eliminate the agent, infections may persist and become chronic.

          Some immunologic mechanisms, such as CTL responses, that are involved in resolving an ongoing infection caused by an intracellular infectious agent,  
20 may also play a role in preventing new infections. While other immunologic mechanisms, such as a neutralizing antibody, clearly appear to be more important for preventing certain viral infections than for resolving an ongoing infection. In the case of neutralizing  
25 antibodies, antibodies directed against surface antigens can act to neutralize the infectivity of the virus by promoting viral aggregation and ultimately removal of the virus from the bloodstream. Viral infections that are typically blocked by a virus neutralizing antibody, can  
30 also be prevented by immunization with antigens that elicit the same neutralizing antibodies. However, for other intracellular infectious agents, a neutralizing antibody cannot be elicited or, when it is elicited, is insufficient for protection. Nonetheless, protection can  
35 be conferred by the introduction of an appropriate

-8-

immunizing agent. In such cases, the cellular immune mechanisms appear to facilitate ability of the immunizing agent to protect against infection. In order for the immune response to result in protection, the immunizing agent must elicit a strong and persistent CTL response. Murphy et al., in, Virology, 2nd Ed., ed. B. Fields, Raven Press, New York, pp. 469-502 (1990).

Thus, there has been a need for a method of enhancing the immune response to intracellular infectious agents, such as viruses, by eliciting a strong CTL response. The present invention satisfies that need.

#### Summary of the Invention

The present invention provides materials and methods for enhancing the immune response of an individual to an intracellular infectious agent, such as a virus, protozoan, fungus, or bacteria. The materials include vectors encoding a costimulatory factor for T cell activation (hereinafter "costimulatory factor") and a "target antigen" from the infectious agent. The vector, either as a polynucleotide or packaged into a virus assembly, is either directly administered to the individual to be treated, or alternatively, is inserted into a cell which is then administered to the individual to be treated. The administration of the genetic information encoding the costimulatory factor and the target antigen enhances the immune response by, inter alia, eliciting the generation of CTLs directed at cells infected with the infectious agent from which the target antigen is derived.

Accordingly, one embodiment of the invention is a recombinant polynucleotide comprised of a region encoding a costimulatory factor operably linked to a transcriptional control region and further comprised of a region encoding a target antigen polypeptide operably

-9-

linked to a transcriptional control region. Expression of the costimulatory factor and target antigen polypeptide in an individual confers at least partial immunity in the individual to an intracellular infectious agent that naturally encodes the target antigen polypeptide. The recombinant polynucleotide may be comprised of a viral vector or other vectors as described below.

Another embodiment of the invention is a host cell transformed with a recombinant polynucleotide comprised of a region encoding a costimulatory factor operably linked to a transcriptional control region and with a recombinant polynucleotide comprised of a region encoding a target antigen polypeptide operably linked to a transcriptional control region. Expression of the costimulatory factor and target antigen polypeptide in the individual confers at least partial immunity to an intracellular infectious agent that naturally encodes the target antigen polypeptide.

Still another embodiment of the invention is a method of using a recombinant polynucleotide comprised of a region encoding a costimulatory factor operably linked to a transcriptional control region and with a recombinant polynucleotide comprised of a region encoding a target antigen polypeptide operably linked to a transcriptional control region, the method comprising administering the recombinant polynucleotide to an individual in a therapeutically effective amount; and determining a lessening of a physical symptom associated with a response to infection by an intracellular pathogen that naturally encodes the target antigen.

Yet another embodiment of the invention is a method of using the above-described recombinant polynucleotides comprising transforming a host cell with

-10-

the polynucleotide. Also claimed are host cells prepared by this method, and progeny thereof.

Brief Description of the Drawing

Figure 1 is a line drawing of two virus  
5 vectors.

Detailed Description of the Invention

The critical role of costimulatory factors is to make cells expressing the desired target antigens, such as viral antigens, effective APCs in order to  
10 facilitate T cell activation. By creating a system which expresses a costimulatory factor (or a functional portion thereof) concurrently with a target antigen, the resulting response leads to elimination of infected host cells and stronger protection of uninfected hosts cells  
15 against new infections.

The invention teaches that immunotherapy that introduces into an individual genetic information encoding the functional portions of a costimulatory factor and a target antigen can be used to activate  
20 and/or enhance the immune response of an infected mammalian host. The enhancement includes a cellular response to infections caused by the intracellular infectious agent from which the target antigen is derived, and an induced protective immune response in  
25 uninfected cells to prevent new infection to the infectious agent.

The following terms used herein are defined as follows.

The term "polypeptide" refers to a polymer of  
30 amino acids and does not refer to a specific length of the product; thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide. This term also does not refer to or exclude post-expression modifications of the polypeptide, for example,  
35 glycosylations, acetylations, phosphorylations and the

-11-

like. Included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), polypeptides with substituted linkages, as well as  
5 other modifications known in the art, both naturally occurring and non-naturally occurring.

"Transformation", as used herein, refers to the insertion of an exogenous polynucleotide into a host cell, irrespective of the method used for the insertion,  
10 for example, direct uptake, transduction, f-mating or electroporation. The exogenous polynucleotide may be maintained as a non-integrated vector, for example, a plasmid, or alternatively, may be integrated into the host cell genome.

15 "Treatment" as used herein refers to prophylaxis and/or therapy. The effectiveness of a treatment can be determined by the alleviation of one or more symptoms normally associated with a disease caused by an intracellular pathogen.

20 "Intracellular pathogen" refers to an agent capable of causing a disease state in a susceptible individual, in which part or all of the replicative cycle of the pathogen occurs within the cells of an infected individual. Intracellular pathogens include, for  
25 example, protozoa, fungi, bacteria, and viruses.

"Helper cells" or " $T_H$  cells" are a functional subclass of T cells which can help to generate cytotoxic T cells and cooperate with B cells in the production of an antibody response. Helper cells usually recognize  
30 antigen in association with class II MHC molecules.

An "antigen specific T cell clone" is comprised of the progeny of a single cell; the cells in this type of clone are of the same phenotype and are all targeted towards the same antigen. Methods of preparing antigen-  
35 specific T cell clones are known in the art.

-12-

The term "recombinant expression vector" refers to a replicable unit of DNA or RNA in a form capable of being introduced into a target cell by transformation, electroporation, transduction or viral infection, and  
5 which codes for the expression of a heterologous structural coding sequence, for example, a cytokine, which is transcribed into mRNA and translated into protein under the control of elements having a regulatory role in gene expression. Such vectors will preferably  
10 also contain appropriate transcription and translation control sequences, including initiation sequences operably linked to the coding sequence.

"Recombinant," as used herein, means that a particular DNA sequence is the product of various  
15 combinations of cloning, restriction, and ligation steps resulting in a construct having a structural coding sequence distinguishable from homologous sequences found in natural systems. Generally, DNA sequences encoding the structural coding sequence, for example cytokines,  
20 can be assembled from cDNA fragments and short oligonucleotide linkers, or from a series of oligonucleotides, to provide a synthetic gene which is capable of being expressed in a recombinant transcriptional unit. Such sequences are preferably  
25 provided in the form of an open reading frame uninterrupted by internal nontranslated sequences, or introns, which are typically present in eukaryotic genes. Genomic DNA containing the relevant sequences could also be used. Sequences of non-translated DNA may be present  
30 5' or 3' from the open reading frame, where such sequences do not interfere with manipulation or expression of the coding regions.

"Recombinant host cells", "host cells", "cells", "cell lines", "cell cultures", and other such  
35 terms denoting microorganisms or higher eukaryotic cell

-13-

lines cultured as unicellular entities refer to cells which can be, or have been, used as recipients for recombinant vectors or other transfer polynucleotides, and include the progeny of the original cell which has  
5 been transfected. It is understood that the progeny of a single cell may not necessarily be completely identical in morphology or in genomic or total DNA complement as the original parent, due to natural, accidental, or deliberate mutation.

10 A CTL is "cytolytically specific for" cells expressing antigens if the CTL is capable of selectively recognizing and lysing the cells bearing the antigen. A CTL is "cytolytically reactive against" cells expressing antigens if the CTL is capable of lysing the cells  
15 bearing the antigen, without regard to its ability to selectively recognize such cells.

"Antigen specific expression" refers to expression that occurs when the T cell recognizes its cognate antigen.

20 "Cognate antigen" refers to an antigen, a peptide of which when associated with an MHC molecule forms a ligand that binds to a lymphocyte that recognizes it and causes triggering of signals for the effector function of the cell and/or for proliferation.

25 "Target antigen" refers to an antigen that when expressed in a cell can elicit a CTL response directed at cells expressing that antigen.

30 An "agretope" is the portion of an antigen or antigenic fragment which allows it to bind to an MHC molecule.

An "activated lymphocyte" is one that as a result of binding of a cognate antigen peptide:MHC molecule is producing polypeptide stimulatory factors (including, for example, cytokines) at a level that is  
35

-14-

elevated relative to the lymphocyte without the bound ligand.

A "transcriptional regulatory region" encompasses all the elements necessary for transcription, and may include elements necessary for regulation and cell-specific transcription. Thus, a transcriptional regulatory region includes at least the promoter sequence, and may also include other regulatory sequences such as enhancers, and transcription factor binding sites.

"Operably linked" refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. For instance, a promoter is operably linked to a coding sequence if the promoter affects its transcription or expression.

The term "recombinant" polynucleotide or nucleic acid refers to one which is not naturally occurring, or is made by the artificial combination of two otherwise separated segments of sequence. This artificial combination is often accomplished by either chemical synthesis means, or by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques. Such is usually done to replace a codon with a redundant codon encoding the same or a conservative amino acid, while typically introducing or removing a sequence recognition site. Alternatively, it is performed to join together nucleic acid segments of desired functions to generate a desired combination of functions.

"Regulatory Sequences" refer to those sequences normally associated with (for example within 50 kb) of the coding region of a locus which affect the expression of the gene (including transcription of the gene, and translation, splicing, stability, or the like of the



-15-

messenger RNA). Regulatory sequences include, inter alia, promoters, enhancers, splice sites and polyadenylation sites.

5 The "sense strand" of a nucleic acid contains the sequence that has sequence homology to that of the cognate mRNA. The "anti-sense strand" contains a sequence which is complementary to that of the "sense strand".

10 An "individual" as used herein refers to vertebrates, particularly members of the mammalian species, and includes, but is not limited to, domestic animals, sports animals, and primates, including humans.

"Immunization" refers conferring a state of immunity upon an individual by administration of a  
15 therapeutic or prophylactic agent.

By "immunity" is meant a lessening and/or prevention of one or more physical symptoms associated with a response to infection by the pathogen from which the target antigen was derived.

20 An "immune response" to a composition or vaccine is the development in the host of a cellular and/or antibody-mediated immune response to the intracellular infectious agent that encodes the target antigen. Usually, such a response comprises the  
25 individual producing CTLs and/or B cells and/or a variety of classes of T cells directed specifically to APCs expressing the target antigen.

A "therapeutically effective amount" of a composition is a dose sufficient to induce an immune  
30 response and/or to confer immunity against an intracellular infectious agent that naturally encodes the target antigen.

The practice of the present invention will employ, unless otherwise indicated, conventional  
35 techniques of molecular biology, microbiology,

-16-

recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See e.g., Sambrook, Fritsch, and Maniatis, MOLECULAR CLONING: A LABORATORY MANUAL, Second Edition (1989), OLIGONUCLEOTIDE SYNTHESIS (M.J. Gait Ed., 1984), ANIMAL CELL CULTURE (R.I. Freshney, Ed., 1987), the series METHODS IN ENZYMOLOGY (Academic Press, Inc.); GENE TRANSFER VECTORS FOR MAMMALIAN CELLS (J.M. Miller and M.P. Calos Eds. 1987), HANDBOOK OF EXPERIMENTAL IMMUNOLOGY, (D.M. Weir and C.C. Blackwell, Eds.); CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, (F.M. Ausubel, R. Brent, R.E. Kingston, D.D. Moore, J.G. Siedman, J.A. Smith, and K. Struhl Eds. 1987); and CURRENT PROTOCOLS IN IMMUNOLOGY (J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach and W. Strober Eds. 1991). All patents, patent applications, and publications mentioned herein, both supra and infra, are hereby incorporated herein by reference.

In accordance with the invention, APCs which express a target antigen and are capable of stimulating a T cell response, preferably a CTL response, are created either in vivo or in vitro by the insertion of one or more recombinant polynucleotides containing a sequence encoding at least one costimulatory factor and at least one target antigen polypeptide, such that the costimulatory factor(s) and the target antigen polypeptide(s) are expressed within the recipient host cell.

The costimulatory factor expressed from the recombinant polynucleotide will include at least a portion of the protein sufficient to allow binding of the cell expressing the costimulatory factor to its costimulatory ligand. Methods for determining such binding are known in the art. See, for example, Linsley et al. who describe a procedure wherein the cells to be

-17-

tested are labeled with  $^{51}\text{Cr}$ , and then incubated with either  $\text{CD28}^+$  and  $\text{CD28}^-$  CHO cells, and the adhesion of the labelled cells to the CHO cells is determined by  $^{51}\text{Cr}$  release. Proc. Natl. Acad. Sci. USA, 87:5031-5035

- 5 (1990). The extracellular domains and transmembrane domains of the costimulatory factors are usually included in the polypeptide, and in preferred embodiments, the entire costimulatory factor is encoded. The sequences for polynucleotides encoding costimulatory factors and  
10 the functional domains are known, and are described in, for example, Linsley et al. (1990) (human) and Freeman et al., J. Immunol., 143:2714-2722 (1989) (mouse).

- The target antigen polypeptide expressed from the recombinant polynucleotide is all or a fragment of a  
15 target antigen that is naturally encoded in the pathogenic intracellular microorganism against which an enhanced or augmented immune response is desired, and is comprised of one or more epitopes from that microorganism. Target antigens are preferably from  
20 viruses, and particularly viruses that result in chronic infections, for example, the hepadnaviruses (including HBV), the lentiviruses (including HIV), herpesviruses (including HSV-1, HSV-2, EBV, CMV, VZV, and HHV-6), and the flaviviruses/pestiviruses (including HCV). Also  
25 included as viruses that cause chronic viral infections are human retroviruses, for example, human T lymphotropic viruses (HTLV-1 and HTLV-2) that cause T cell leukemia and myelopathies. Other organisms that cause chronic infections include, for example, pathogenic protozoa,  
30 (e.g., Pneumocystis carinii, trypanosoma, malaria and Toxoplasma gondii), bacteria (e.g., mycobacteria, salmonella and listeria) and fungi (e.g. candida and aspergillus).

- The nucleotide sequences of a number of these  
35 viruses, including different species, strains, and

-18-

isolates are known in the art. For reviews see: Robinson (1990) (Hepadnaviridae); Levy, Microbiological Reviews, 57:183-289 (1993) (HIV); and Choo et al., Seminars in Liver Disease, 12:279-288. (1992) (HCV).

- 5 Particularly suitable target antigens are those which induce a T cell response, and particularly a CTL-response during infection. These may include, for example, from HBV, the core antigen, the E antigen, and the surface antigen (HBsAg). Polynucleotide sequences for HBsAg  
10 including the pre-S1, pre-S2 and S regions from a variety of surface antigen subtypes are known in the art. See, for example, Okamoto et al., J. Gen. Virol., 67:1383-1389 (1986); Genbank accession numbers D00329 and D00330. The polynucleotide sequences encoding HIV glycoprotein gp160  
15 and other antigenic HIV regions are known in the art. Lautenberger et al., Nature, 313:277-284 (1985); Starcich et al., Cell, 45:637-648 (1986); Wiley et al., Proc. Natl. Acad. Sci. USA, 83:5038-5042 (1986); and Modrow et al., J. Virol., 61:570-578 (1987).

- 20 It is within the scope of the invention to include nucleotides encoding two or more target antigen polypeptides that may or may not be fused. The two target antigen polypeptides may be from the same pathogenic intracellular microorganism, or when it is  
25 desirable to enhance the immune response to more than one microorganism, from differing microorganisms.

- The sequences encoding the costimulatory factor and the target antigen polypeptide are operably linked to a transcriptional control region. Transcriptional  
30 control regions are known in the art, and include, for example, regions isolated from the following: the human cytomegalovirus (HCMV) IE94 promoter region (Boshart et al., Cell, 41:521-530 (1985)); the human IL-2 gene (Fujita et al., Cell, 46:401-407 (1986)); the human IFN- $\gamma$   
35 gene (Ciccarone et al., J. Immunol., 144:725-730 (1990));

-19-

the human IL-3 gene (Shoemaker et al., Proc. Natl. Acad. Sci. USA, 87:9650-9654 (1990)); the human IL-4 gene (Arai et al., J. Immunol., 142:274-282 (1989)); the human lymphotoxin gene (Nedwin et al., Nucl. Acids. Res., 13:6361-6373 (1985)); the human granulocyte-macrophage CSF (GM-CSF) gene (Miyatake et al., EMBO J., 4:2561-2568 (1985)); the human perforin gene (Lichtenheld et al., J. Immunol., 143:4267-4274 (1989)); the human 519 gene (Manning et al., J. Immunol., 148:4036-4042 (1992)); the human granzyme B (CTLA-1) gene (Haddad et al., Gene, 87:265-271 (1990)); the human CTLA-4 gene (Harper et al., J. Immunol., 147:1397-1044 (1991)); the human CGL-2 gene (Heusel et al., J. Biol. Chem., 266:6152-6158 (1991)); the human granzyme H gene (Haddad et al., Int. Immunol., 3:57-66 (1990)); the human IL-2 receptor,  $\alpha$  chain gene (Cross et al., Cell, 49:47-56 (1987)); the Murine T cell activation 3 (TCA-3) gene (Wilson et al., J. Immunol., 141:1563-1570 (1988)); and the human CD69 gene.

In some embodiments of the invention, the transcriptional control regions are hybrids. For example, enhancer regions (e.g., from the HCMV IE transcriptional control region and/or from the SV40 early promoter region) may be inserted upstream of the transcriptional control regions. Alternatively, or in addition, multimeric transcription factor binding sites (e.g., NF-AT and/or NF $\kappa$ B) may be inserted into or upstream of the transcriptional control regions, combining the upstream region of one with the proximal region of the other. Secretion signals may also be included where appropriate, whether from a native protein or from other secreted polypeptides of the same or related species, which allow the protein to cross and/or lodge in cell membranes, and thus attain its functional topology, or to be secreted from the cell.

35

-20-

In addition, it is useful to include in the recombinant polynucleotides a positive marker that enables the selection of cells carrying the recombinant polynucleotide. The positive selectable marker may be a gene which, upon being introduced into the host cell expresses a dominant phenotype permitting positive selection of cells carrying the gene. Genes of this type are known in the art, and include, *inter alia*, hygromycin-B phosphotransferase gene (hph) which confers resistance to hygromycin B, the aminoglycoside phosphotransferase gene (neo or aph) from Tn5 which codes for resistance to the antibiotic G418, the dihydrofolate reductase (DHFR) gene, the adenosine deaminase gene (ADA), and the multi-drug resistance (MDR) gene.

The sequences encoding the costimulatory factor and the target antigen polypeptide(s) may be on separate polynucleotides, but preferably are on the same polynucleotide. These encoding sequences may also be under the control of separate transcriptional control sequences, or under the control of the same transcriptional control sequence.

In addition to transcriptional control regions, in some embodiments, the polynucleotides encoding the costimulatory factor and target antigen(s) are in the form of recombinant expression vectors.

Techniques for nucleic acid manipulation are described generally, for example, in Sambrook et al. (1989), Ausubel et al. (1987); and in Annual Reviews of Biochemistry, 61:131-156 (1992). Reagents useful in applying such techniques, such as restriction enzymes and the like, are widely known in the art and commercially available from a number of vendors.

Large amounts of the polynucleotides used to create the cells of the present invention may be produced by replication in a suitable host cell. The natural or

-21-

synthetic polynucleotide fragments coding for a desired fragment may be incorporated into recombinant nucleic acid constructs, typically polynucleotide constructs, capable of introduction into and replication in a prokaryotic or eukaryotic cell. Usually the constructs will be suitable for replication in a unicellular host, such as yeast or bacteria, but may also be intended for introduction to, with and without and integration within the genome, cultured mammalian or plant or other eukaryotic cell lines. The purification of nucleic acids produced by the methods of the present invention are described, e.g., in Sambrook et al. (1989).

The polynucleotides used in the present invention may also be produced in part or in total by chemical synthesis, e.g., by the phosphoramidite method described by Beaucage and Carruthers, Tetra. Letts., 22:1859-1862 (1981) or the triester method according to the method described by Matteucci et al., J. Am. Chem. Soc., 103:3185 (1981), and may be performed on commercial automated oligonucleotide synthesizers. A double-stranded fragment may be obtained from the single stranded product of chemical synthesis either by synthesizing the complementary strand and annealing the strand together under appropriate conditions or by adding the complementary strand using DNA polymerase with an appropriate primer sequence.

Polynucleotide constructs prepared for introduction into a prokaryotic or eukaryotic host cell for replication will typically comprise a replication system recognized by the host, including the intended recombinant polynucleotide fragment encoding the desired polypeptide. Such vectors may be prepared by means of standard recombinant techniques well known in the art and discussed, for example, in Sambrook et al. (1989) or Ausubel et al. (1987).

-22-

Preferably, during the cloning phase, the polynucleotide construct will contain a selectable marker, a gene encoding a protein necessary for the survival or growth of a host cell transformed with the vector. The presence of this gene ensures the growth of only those host cells which express the inserts. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxic substances, e.g. ampicillin, neomycin, methotrexate, etc.; (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g. the gene encoding D-alanine racemase for Bacilli. The choice of the proper selectable marker will depend on the host cell, and appropriate markers for different hosts are well known in the art.

The recombinant polynucleotides encoding the costimulatory factor and target antigen polypeptide may be introduced into individuals in several ways. For example, the polynucleotides may be introduced ex vivo into a host cell, for example, dendritic cells, or cells from a skin biopsy. The cells containing the recombinant polynucleotide may be used to confer immunity to individuals. The cells are usually administered by infusion, with each infusion in a range of at least  $10^6$  to  $10^{10}$  cells/ $m^2$ , preferably in the range of at least  $10^7$  to  $10^9$  cells/ $m^2$ . The clones may be administered by a single infusion, or by multiple infusions over a range of time. However, since different individuals are expected to vary in responsiveness, the type and amount of cells infused, as well as the number of infusions and the time range over which multiple infusions are given are determined by the attending physician or veterinarian, and can be determined by routine examination.

The polynucleotides encoding the costimulatory factor and the target antigen polypeptide may be



-23-

introduced into the desired cell ex vivo by means known in the art, including, for example, transformation, electroporation, lipofection, and transduction, including the use of adeno-associated viral (AAV) vectors, and particularly using methods of retroviral gene transfer known in the art.

Various infection techniques have been developed which utilize recombinant infectious virus particles for gene delivery. This represents a preferred approach to the present invention. The viral vectors which have been used in this way include virus vectors derived from simian virus 40 (SV40; Karlsson et al., Proc. Natl. Acad. Sci. USA, 82:158 (1985)), adenoviruses (Karlsson et al., EMBO J., 5:2377 (1986)), AAV (Carter, Current Opinion in Biotechnology 1992, 3:533-539), and retroviruses (Coffin, in Weiss et al. (eds.), RNA Tumor Viruses, 2nd ed., Vol. 2, Cold Spring Harbor Laboratory, New York, 1985, pp. 17-71). Thus, gene transfer and expression methods are numerous but essentially function to introduce and express genetic material in mammalian cells. Several of the above techniques have been used to transduce hematopoietic or lymphoid cells, including calcium phosphate transfection (Berman et al. (1984)), protoplast fusion (Deans et al. (1984)), electroporation (Cann et al., Oncogene, 3:123 (1988)), and infection with recombinant adenovirus (Karlsson et al. (1986)); Reuther et al., Mol. Cell. Biol., 6:123 (1986); AAV (Carter (1985)) and retrovirus vectors (Overell et al., Oncogene 4:1425 (1989)).

Retroviral vectors provide a highly efficient method for gene transfer into eukaryotic cells which is the preferred method for the delivery of the polynucleotides of the invention. Moreover, retroviral integration takes place in a controlled fashion and

35

-24-

results in the stable integration of one or a few copies of the new genetic information per cell.

Retroviruses are a class of viruses which replicate using a virus-encoded, RNA-directed DNA polymerase, or reverse transcriptase, to replicate a viral RNA genome to provide a double-stranded DNA intermediate which is incorporated into chromosomal DNA of an avian or mammalian host cell. Most retroviral vectors are derived from murine retroviruses.

Retroviruses adaptable for use in accordance with the present invention can, however, be derived from any avian or mammalian cell source. These retroviruses are preferably amphotropic, meaning that they are capable of infecting host cells of a broad host range of several species, including humans.

A characteristic feature of retroviral genomes (and retroviral vectors used as described herein) is the retroviral long terminal repeat, or LTR, which is an untranslated region of about 600 base pairs found in slightly variant forms at the 5' and 3' ends of the retroviral genome. When incorporated into DNA as a provirus, the retroviral LTR includes a short direct repeat sequence at each end and signals for initiation of transcription by RNA polymerase II and 3' cleavage and polyadenylation of RNA transcripts. The LTR contains all other *cis*-acting sequences necessary for viral replication.

A "provirus" refers to the DNA reverse transcript of a retrovirus which is stably integrated into chromosomal DNA in a suitable host cell, or a cloned copy thereof, or a cloned copy of unintegrated intermediate forms of retroviral DNA. Forward transcription of the provirus and assembly into infectious virus occurs in the presence of an appropriate helper virus or in a cell line containing appropriate

-25-

sequences enabling encapsidation without coincident production of a contaminating helper virus. Mann et al., describe the development of "packaging" cell lines (e.g.,  $\Psi$ 2) which can be used to produce helper-free stocks of recombinant retrovirus. Cell, 33:153 (1983).

Packaging cell lines contain integrated retroviral genomes which lack sequences required *in cis* for encapsidation, but which provide all necessary gene product *in trans* to produce intact virions. The RNA transcribed from the integrated mutant provirus cannot itself be packaged, but these cells can encapsidate RNA transcribed from a recombinant retrovirus introduced into the same cell. The resulting virus particles are infectious, but replication-defective, rendering them useful vectors which are unable to produce infectious virus following introduction into a cell lacking the complementary genetic information enabling encapsidation.

Encapsidation in a cell line harboring *trans*-acting elements encoding an ecotropic viral envelope (e.g.,  $\Psi$ 2) provides ecotropic (limited host range) progeny virus. Alternatively, assembly in a cell line containing amphotropic packaging genes (e.g., PA317, ATCC CRL 9078) provides amphotropic progeny virus. Miller and Buttimore, Mol. Cell. Biol., 6:2895 (1986). Such packaging cell lines provide the necessary retroviral gag, pol and env proteins *in trans*. This strategy results in the production of retroviral particles which are highly infectious for mammalian cells, while being incapable of further replication after they have integrated into the genome of the target cell. The product of the env gene is responsible for the binding of the retrovirus to viral receptors on the surface of the target cell and therefore determines the host range of the retrovirus. The PA317 cells produce retroviral particles with an amphotropic envelope protein, which can

-26-

transduce cells of human and other species origin. Other packaging cell lines produce particles with ecotropic envelope proteins, which are able to transduce only mouse and rat cells.

5           Numerous retroviral vector constructs have been used successfully to express many foreign genes (see, e.g., Coffin (1985). Retroviral vectors with inserted sequences are generally functional, and few sequences that are consistently inhibitory for retroviral infection  
10 have been identified. Functional polyadenylation motifs inhibit retroviral replication by blocking retroviral RNA synthesis, and there is an upper size limit of approximately 11 kb of sequence which can be packaged into retroviral particles; however, the presence of  
15 multiple internal promoters, initially thought to be problematic, was found to be well tolerated in several retroviral constructs. Coffin (1985); and Overell et al., Mol. Cell. Biol., 8:1803 (1983).

          Many gene products have been expressed in  
20 retroviral vectors. This can either be achieved by placing the sequences to be expressed under the transcriptional control of the promoter incorporated in the retroviral LTR, or by placing them under the control of a heterologous promoter inserted between the LTRs.  
25 The latter strategy provides a way of coexpressing a dominant selectable marker gene in the vector, thus allowing selection of cells which are expressing specific vector sequences.

          In other embodiments of the invention, the  
30 recombinant polynucleotides encoding the costimulatory factor and target antigen polypeptide are introduced directly into the individual to be treated and/or immunized. In one embodiment the polynucleotides of the invention are administered directly to the individual to  
35 be treated. In this method it is preferred that the

-27-

polynucleotide encode both the costimulatory factor and the target antigen polypeptide. In addition, it is preferred that the polynucleotide be in the form of an expression vector.

5           The polynucleotides are mixed with suitable excipients, and administered to the individual by any suitable means known in the art, including, for example parenteral (including, for example, intravenous, intraperitoneal, intramuscular, and subcutaneous)  
10 ingestion, lipofection, and transdermal. Suitable excipients are known in the art, and may be dependent upon the species of the individual to which the polynucleotides are administered as well as the mode of administration. The amount of polynucleotide to be  
15 administered to the individual is an amount sufficient to render immunity to the immunized individual. This amount will vary depending upon the individual treated, and will be determined by the physician or veterinarian rendering the treatment. The amount to be administered as well as  
20 the time of administration (prior to or post-infection) and the number of doses whether single or multiple, is determined by routine methods known to those of skill in the art.

          In another embodiment of the invention, the  
25 polynucleotides of the invention are encapsidated in virions, and the individual is treated with the encapsidated polynucleotide. The virions used may be any of those that are known in the art to be suitable for gene therapy procedures, several of which are discussed  
30 above for the introduction of the polynucleotides into a cell ex vivo. The mode of administration is dependent upon the virion used, and may include, for example, those listed above for administration of unencapsidated polynucleotides. The virions are prepared in a suitable  
35 excipient, and administered to the individual. The

-28-

amount to be administered as well as the time of administration (prior to or post-infection) and the number of doses whether single or multiple, is determined by the administering physician or veterinarian, and is obtainable by routine methods known to those of skill in the art.

The examples presented below are provided as a further guide to the practitioner of ordinary skill in the art, and are not to be construed as limiting the invention in any way.

#### Example 1

##### Design of an Expression Vector Encoding a B7 Polypeptide and GSVH c-polypeptide as a Viral Target-Antigen Polypeptide

Chronic ground squirrel hepatitis virus (GSVH) infection of Beechey ground squirrels is a model system for HBV infection in humans. (Cf. Seeger et al., J. Virol., 51:367-375 (1984)). The present example describes a retroviral vector construct for expression of the B7 gene and a gene encoding the c-antigen (cAg) of GSVH.

The vector construct utilizes the Moloney murine leukemia virus (MMLV) based replication-incompetent vector pMV-7 (Ausubel et al. (1989); and Kirschmeier et al., DNA, 7:219-225 (1988)). pMV-7 contains a neomycin resistant gene under the control of the HSV thymidine kinase (TK) promoter, thus allowing selection in tissue culture of cells containing the vector.

The GSHV c-gene including the precore sequence is used as a polynucleotide sequence encoding a target antigen. The GSVH c-gene is isolated from the viral genome (EMBC/Genbank Accession Number K02715) by polymerase chain reaction (PCR). Marion et al., Proc.

-29-

Natl. Acad. Sci. USA, 77:2941-2945 (1980) and Seeger (1984). The isolated GSHV c-gene is then introduced into the pMV-7 vector under control of the MMLV LTR.

Human B7 cDNA (EMBL/Genbank Accession Number M27533) is cloned as cDNA amplified by PCR from the B7 mRNA of the Raji human B cell line using primers designed from the published cDNA sequence. Freeman (1989). cDNA encoding the B7-1 gene was introduced into the same vector as the GSVH c-gene under control by the CMV immediate early promoter. Gaballe et al., J. Virol., 62:3334-3340 (1988).

The pMV-7 based vector construct encoding the B7 polypeptide and cAg polypeptide was transfected into a retroviral packaging cell line, psi-2. Miller et al., Mol. Cell. Biol., 6:2895-2902 (1986). The transfected cells are then selected by growing in a culture medium containing neomycin. Replication-incompetent retrovirus with an amphotropic envelope produced by the cells grown in the neomycin culture were found in the culture medium.

#### Example 2

##### Design of an Expression Vector Encoding a B7 Polypeptide and GSVH GSHsAg-polypeptide as a Viral Target-Antigen Polypeptide

The construct is prepared as in Example 1, except that the GSVH polynucleotide encoding ground squirrel hepatitis surface antigen (GSHsAg) including the pre-S1, pre-S2 and S regions is substituted for that encoding GSVH cAg. The polynucleotide sequence encoding the aforementioned S regions is described in Seeger et al. (1984).

-30-

Example 3Use of a Vector Encoding B7 Polypeptide  
and GSHsAg to Confer Immunity to  
Uninfected Individuals to GSHV

5           A therapeutically effective amount of a  
composition comprised of an infectious retroviral vector  
packaged in an amphotropic envelope ( $10^7$  tissue culture  
infectious units) containing polynucleotide sequences  
encoding a B7 polypeptide and a GSHsAg polypeptide is  
10 administered parenterally to an uninfected and GSHV  
susceptible Beechey ground squirrel. Seeger et al.  
(1984). The vector is of the construction described in  
Example 2. An "uninfected" GSHV susceptible ground  
squirrel has no detectable serum antibody to ground  
15 squirrel hepatitis virus core antigen (anti-GSHcAg) or  
antibody to ground squirrel hepatitis virus surface  
antigen (anti-GSHsAg). The parenteral administration of  
a retroviral vector containing the B7 gene and GSHV gene  
results in a serum anti-GSHsAg response and a CTL  
20 response directed at cells expressing GSHsAg.

The dual response, i.e., serum and CTL, confers  
at least partial immunity against future infection by  
GSHV on the uninfected ground squirrel.

25

Example 4Use of A Vector Encoding B7 Polypeptide  
and GSHsAg Polypeptide for Treatment  
of Chronic Virus Infection

30           Two different methods may be used to  
administer polynucleotides encoding a B7 polypeptide and  
a viral target antigen to animals chronically infected  
with GSHV for treatment of an infection.

35



- 31 -

Delivery of the Vector Encoding the B7 Polypeptide and GSHsAg Polypeptide Directly to an Infected Mammal

An infectious retroviral vector packaged in an amphotropic envelope and encoding a B7 polypeptide and a GSHcAg polypeptide are constructed as in Example 1. The vector is administered parenterally in a therapeutically effective amount to a ground squirrel chronically infected with GSHV.

The effect of the expression of polypeptides from the retroviral vector on the immune response by the ground squirrel, including a CTL response directed at cells expressing GSHcAg, is monitored. In addition, the effect on the chronicity of the disease, including the presence of viral DNA, the presence of GSHsAg and pathogenic effects associated with the disease is monitored. Diminution in physical symptomology and/or in GSHsAg and/or in GSHV DNA in the treated individual is indicative of alleviation and/or termination of the chronic disease caused by GSHV.

Treatment of an Infected Mammal with Cells Transfected ex vivo with a Vector Encoding B7 Polypeptide and GSH cAg

Fibroblast cells isolated from a skin biopsy of the infected individual are grown in culture, and are transfected with a retroviral vector encoding a B7 polypeptide and a GSHcAg polypeptide. The vector is constructed as described in Example 1. Infected (transduced) cells are then selected by growing cells in a culture medium containing neomycin. The cells expressing GSHcAg are identified by using fluorescent staining (IFA) with anti-HBc and B7 protein expression using ELISA with anti-B7 monoclonal antibody (mAb). A therapeutically effective amount of the autologous cells expressing GSHcAg and B7 are infused intravenously into the GSHV infected ground squirrel.

-32-

The effect of the expression of polypeptides from the retroviral vectors in the implanted cells on the immune response by the ground squirrel, including a CTL response directed at cells expressing GSHcAg, is monitored. In addition, the effect on the chronicity of the disease, including the presence of viral DNA, the presence of GSHsAg and pathogenic effects associated with the disease is monitored. Diminution in physical symptomology and/or in GSHsAg and/or in GVSH DNA in the treated individual is indicative of alleviation and/or termination of the chronic disease caused by GSHV.

#### Example 5

##### Construction of retroviral vectors to express B7 and HBS

Figure 1 depicts recombinant retroviral vectors for the demonstration of the enhancement of the immune response to hepatitis B virus surface antigen (HBS) by co-expression with B7-1 in cells *in vivo*. Retroviral vector pMV-7 DNA was used to construct recombinant vectors 907 with the HBS coding sequence inserted at the polylinker of pMV-7; and recombinant vector 1016 with the HBS coding sequence, a cap independent translation element (CITE) of encephalomyocarditis virus (EMC) and the coding sequence for murine B7-1 all in the same reading frame inserted at the polylinker of pMV-7. Each recombinant vector was used to transfect by the calcium phosphate DNA method a murine Balbc packaging cell line and cells containing the respective vectors were selected by growth in cell culture medium containing neomycin. The packaging cell population neomycin selected to contain recombinant vector 907 and those selected for recombinant vector 1016 released virus that could be assayed by the ability to confer neomycin resistance to Balbc 3T3 cells. Neomycin resistant Balbc 3T3 cells infected with recombinant virus 907 were shown to release HBS by ELISA. Neomycin resistant Balbc 3T3 cells

-33-

infected with recombinant virus 1016 were shown to express HBS as above and the B7-1 protein by FACS analysis using monoclonal antibody to the B7-1 protein. Cells ( $2 \times 10^7$ ) of each respective type and non-transfected Balbc 3T3 cells were each inoculated into separate groups of 10 Balbc mice by the intraperitoneal route for study of the immune response to HBS. Anti-HBS measured by ELISA, proliferation of spleen cells exposed to HBS in vitro and cytotoxic activity of spleen cells by chromium 51 release from Balbc 3T3 cells expressing HBS are assayed in 5 mice of each group at 2 weeks and 5 mice of each group at 4 weeks post inoculation. In Figure 1, LTR represents the long terminal repeats of the retroviral vector, TK represents the thymidine kinase promoter of herpes simplex virus, Neo represents a gene conferring neomycin resistance.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be apparent to those skilled in the art that certain changes and modifications may be practiced. Therefore, the description and examples should not be construed as limiting the scope of the invention which is delineated by the appended claims.

30

35

-34-

## WHAT IS CLAIMED:

1. A recombinant polynucleotide comprised of a region encoding a costimulatory factor operably linked to  
5 a transcriptional control region and further comprised of a region encoding a target antigen polypeptide operably linked to a transcriptional control region.
2. The recombinant polynucleotide according to  
10 claim 1 wherein the costimulatory factor is selected from the group consisting of B7-1, B7-2 and B7-3.
3. The recombinant polynucleotide according to  
15 claim 1, wherein expression of the costimulatory factor and target antigen polypeptide in an individual confers at least partial immunity in the individual to an intracellular infectious agent that naturally encodes the target antigen polypeptide.
- 20 4. The recombinant polynucleotide according to claim 1 wherein the target antigen is naturally encoded in a virus.
- 25 5. The recombinant polynucleotide according to claim 3 wherein the target antigen is naturally encoded in a hepatitis virus.
- 30 6. The recombinant polynucleotide according to claim 3 wherein the target antigen is naturally encoded in a retrovirus.
- 35 7. The recombinant polynucleotide according to claim 3 wherein the target antigen is naturally encoded in human immunodeficiency virus (HIV).

-35-

8. The recombinant polynucleotide according to claim 3 wherein the target antigen is naturally encoded in Hepatitis C virus (HCV).

5 9. The recombinant polynucleotide according to claim 1 wherein the target antigen is naturally encoded in a protozoan.

10 10. The recombinant polynucleotide according to claim 1 wherein the target antigen is encoded in a fungus.

15 11. The recombinant polynucleotide according to claim 1 wherein the target antigen is naturally encoded in a bacterium.

20 12. The recombinant polynucleotide according to claim 1 wherein the target antigen is encoded in a parasitic agent.

13. An expression vector comprised of the recombinant polynucleotide according to claim 1.

25 14. An expression vector comprised of the recombinant polynucleotide according to claim 2.

15. An expression vector comprised of the recombinant polynucleotide of claim 3.

30 16. A viral vector comprised of the recombinant polynucleotide according to claim 1.

35 17. A viral vector comprised of the recombinant polynucleotide according to claim 2.

-36-

18. A viral vector comprised of the recombinant polynucleotide of claim 3.

19. A host cell transformed with a recombinant polynucleotide comprised of a region encoding a costimulatory factor operably linked to a transcriptional control region and with a recombinant polynucleotide comprised of a region encoding a target antigen polypeptide operably linked to a transcriptional control region.

20. The host cell according to claim 19 wherein the costimulatory factor is selected from the group consisting of B7-1, B7-2 and B7-3.

21. The host cell of claim 19 wherein expression of the costimulatory factor and target antigen polypeptide in an individual confers at least partial immunity in the individual to an intracellular infectious agent that naturally encodes the target antigen polypeptide.

22. A method of using a recombinant polynucleotide comprised of a region encoding a costimulatory factor operably linked to a transcriptional control region and with a recombinant polynucleotide comprised of a region encoding a target antigen polypeptide operably linked to a transcriptional control region, the method comprising:

administering the recombinant polynucleotide to an individual in a therapeutically effective amount; and

determining a lessening of a physical symptom associated with a response to infection by an

-37-

intracellular pathogen that naturally encodes the target antigen.

5 23. The method according to claim 22 wherein the costimulatory factor is selected from the group consisting of B7-1, B7-2 and B7-3.

10 24. The method of claim 22, wherein the administered recombinant polynucleotide is contained in a viral vector.

15 25. The method of claim 22, wherein the administered recombinant polynucleotide is contained in a host cell transformed ex vivo with the polynucleotide.

26. A method of using the recombinant polynucleotide of claim 1 comprising transforming a host cell with the polynucleotide.

20 27. A method of using the recombinant polynucleotide of claim 3 comprising transforming a host cell with the polynucleotide.

25 28. A host cell prepared by the method of claim 26 and progeny thereof.

29. A host cell prepared by the method of claim 27 and progeny thereof.

30

35

1/1




FIG. 1



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/04367

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(5) :C12N 5/10, 15/11, 15/12, 15/30, 15/31, 15/33, 15/63

US CL :Please See Extra Sheet

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/172.3, 240.1, 240.2, 252.3, 320.1; 536/23.1, 23.5, 23.7, 23.72, 23.74

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS; DIALOG DATABASES: BIOSIS PREVIEWS, MEDLINE, WORLD PATENT INDEX, CA SEARCH

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Cell, Volume 71, Number 7, issued 24 December 1992, Chen et al., "Costimulation of Antitumor Immunity by the B7 Counterreceptor for the T Lymphocyte Molecules CD28 and CTLA-4," pages 1093-1102, see entire article.	1-29
Y	Progress in Nucleic Acid Research and Molecular Biology, Volume 38, issued 1990, McLachlin et al., "Retroviral-Mediated Gene Transfer," pages 91-135, see entire article.	1-29

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A		document defining the general state of the art which is not considered to be of particular relevance
* E		earlier document published on or after the international filing date
* L		document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
* O		document referring to an oral disclosure, use, exhibition or other means
* P		document published prior to the international filing date but later than the priority date claimed
	* X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
	* Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
	* A	document member of the same patent family

Date of the actual completion of the international search

04 AUGUST 1994

Date of mailing of the international search report

AUG 22 1994

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JOHNNY F. RAILEY II, PH.D. *K. Kuyza for*

Telephone No. (703) 308-0196

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US94/04367

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest.

☒

No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/04367

## A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

435/172.3, 240.1, 240.2, 252.3, 320.1; 536/23.1, 23.5, 23.7, 23.72, 23.74

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

I. Claims 1-21 and 26-29, drawn to a first appearing product, recombinant polynucleotides, vectors comprising the polynucleotides, and host cells comprising the recombinant polynucleotides, as well as a first method of use of the polynucleotides for the transformation of the host cells, classified in class 435, subclass 240.2.

II. Claims 22-24, drawn to a second use of the recombinant polynucleotides, for administration as a therapeutic, classified in class 424, subclass 93A.

III. Claim 25, drawn to a third method, host cells transformed with recombinant polynucleotides administered as a therapeutic, classified in class 424, subclass 93B.

The claims of Group I are drawn a first product and a first method of use of the first product. Groups II and III are drawn to independent and distinct methods which are not so linked by a special technical feature within the meaning of PCT rule 13.2 so as to form a single general inventive concept. PCT Rules 13.1 and 13.2 do not provide for multiple distinct products and methods within a single application.